AstraZeneca's Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
These medicines are essential in preventing RhD immunisation during pregnancy
The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells
Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
The partnership combines Boehringer’s expertise in canine cardiology with Eko’s digital stethoscopes and AI algorithms
Bisoprolol is a highly cardioselective beta-1 adrenergic blocker used to manage high blood pressure,
AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
Allopurinol is used to prevent or lower high uric acid levels in the blood
Subscribe To Our Newsletter & Stay Updated